This study revealed that miR-223 overexpression could enhance the therapeutic effect of doxorubicin for HCC in vitro and in vivo, and the underlying mechanism is through suppression of doxorubicin-induced autophagy via direct targeting of FOXO3a. This evidence concerns the gene FOXO3 and hepatocellular carcinoma.